262 related articles for article (PubMed ID: 35357905)
1.
Rasti AR; Guimaraes-Young A; Datko F; Borges VF; Aisner DL; Shagisultanova E
JCO Precis Oncol; 2022 Mar; 6():e2100370. PubMed ID: 35357905
[TBL] [Abstract][Full Text] [Related]
2. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT
Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640
[TBL] [Abstract][Full Text] [Related]
3. Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA.
Garay JP; Smith R; Devlin K; Hollern DP; Liby T; Liu M; Boddapati S; Watson SS; Esch A; Zheng T; Thompson W; Babcock D; Kwon S; Chin K; Heiser L; Gray JW; Korkola JE
Breast Cancer Res; 2021 Aug; 23(1):81. PubMed ID: 34344439
[TBL] [Abstract][Full Text] [Related]
4. Targeting PIK3CA Alterations in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: New Therapeutic Approaches and Practical Considerations.
Schwartzberg LS; Vidal GA
Clin Breast Cancer; 2020 Aug; 20(4):e439-e449. PubMed ID: 32278641
[TBL] [Abstract][Full Text] [Related]
5. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828
[TBL] [Abstract][Full Text] [Related]
6. Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA
Cheng F; Zhao J; Hanker AB; Brewer MR; Arteaga CL; Zhao Z
Breast Cancer Res Treat; 2016 Dec; 160(3):457-474. PubMed ID: 27771839
[TBL] [Abstract][Full Text] [Related]
7. Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells.
Fujimoto Y; Morita TY; Ohashi A; Haeno H; Hakozaki Y; Fujii M; Kashima Y; Kobayashi SS; Mukohara T
Sci Rep; 2020 Dec; 10(1):21762. PubMed ID: 33303839
[TBL] [Abstract][Full Text] [Related]
8. Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells.
Rexer BN; Chanthaphaychith S; Dahlman K; Arteaga CL
Breast Cancer Res; 2014 Jan; 16(1):R9. PubMed ID: 24451154
[TBL] [Abstract][Full Text] [Related]
9. The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancer.
Janiszewska M; Stein S; Metzger Filho O; Eng J; Kingston NL; Harper NW; Rye IH; Alečković M; Trinh A; Murphy KC; Marangoni E; Cristea S; Oakes B; Winer EP; Krop IE; Russnes HG; Spellman PT; Bucher E; Hu Z; Chin K; Gray JW; Michor F; Polyak K
JCI Insight; 2021 Jun; 6(11):. PubMed ID: 33886505
[TBL] [Abstract][Full Text] [Related]
10. PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers.
Bonazzoli E; Cocco E; Lopez S; Bellone S; Zammataro L; Bianchi A; Manzano A; Yadav G; Manara P; Perrone E; Haines K; Espinal M; Dugan K; Menderes G; Altwerger G; Han C; Zeybek B; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin AD
Gynecol Oncol; 2019 Apr; 153(1):158-164. PubMed ID: 30630630
[TBL] [Abstract][Full Text] [Related]
11. Exploring Biomarkers of Phosphoinositide 3-Kinase Pathway Activation in the Treatment of Hormone Receptor Positive, Human Epidermal Growth Receptor 2 Negative Advanced Breast Cancer.
Kaklamani VG; Richardson AL; Arteaga CL
Oncologist; 2019 Mar; 24(3):305-312. PubMed ID: 30651399
[TBL] [Abstract][Full Text] [Related]
12. Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines.
Kataoka Y; Mukohara T; Shimada H; Saijo N; Hirai M; Minami H
Ann Oncol; 2010 Feb; 21(2):255-262. PubMed ID: 19633047
[TBL] [Abstract][Full Text] [Related]
13. PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.
Majewski IJ; Nuciforo P; Mittempergher L; Bosma AJ; Eidtmann H; Holmes E; Sotiriou C; Fumagalli D; Jimenez J; Aura C; Prudkin L; Díaz-Delgado MC; de la Peña L; Loi S; Ellis C; Schultz N; de Azambuja E; Harbeck N; Piccart-Gebhart M; Bernards R; Baselga J
J Clin Oncol; 2015 Apr; 33(12):1334-9. PubMed ID: 25559818
[TBL] [Abstract][Full Text] [Related]
14. PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib.
Wang L; Zhang Q; Zhang J; Sun S; Guo H; Jia Z; Wang B; Shao Z; Wang Z; Hu X
BMC Cancer; 2011 Jun; 11():248. PubMed ID: 21676217
[TBL] [Abstract][Full Text] [Related]
15. Breast Cancer Mutations HER2V777L and PIK3CAH1047R Activate the p21-CDK4/6-Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance.
Cheng X; Sun Y; Highkin M; Vemalapally N; Jin X; Zhou B; Prior JL; Tipton AR; Li S; Iliuk A; Achilefu S; Hagemann IS; Edwards JR; Bose R
Cancer Res; 2023 Sep; 83(17):2839-2857. PubMed ID: 37272756
[TBL] [Abstract][Full Text] [Related]
16. PIK3CA(H1047R)- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling.
Cheng H; Liu P; Ohlson C; Xu E; Symonds L; Isabella A; Muller WJ; Lin NU; Krop IE; Roberts TM; Winer EP; Arteaga CL; Zhao JJ
Oncogene; 2016 Jun; 35(23):2961-70. PubMed ID: 26640141
[TBL] [Abstract][Full Text] [Related]
17. PI3K activation promotes resistance to eribulin in HER2-negative breast cancer.
Gris-Oliver A; Ibrahim YH; Rivas MA; García-García C; Sánchez-Guixé M; Ruiz-Pace F; Viaplana C; Pérez-García JM; Llombart-Cussac A; Grueso J; Parés M; Guzmán M; Rodríguez O; Anton P; Cozar P; Calvo MT; Bruna A; Arribas J; Caldas C; Dienstmann R; Nuciforo P; Oliveira M; Cortés J; Serra V
Br J Cancer; 2021 Apr; 124(9):1581-1591. PubMed ID: 33723394
[TBL] [Abstract][Full Text] [Related]
18. Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer.
Sukawa Y; Yamamoto H; Nosho K; Kunimoto H; Suzuki H; Adachi Y; Nakazawa M; Nobuoka T; Kawayama M; Mikami M; Matsuno T; Hasegawa T; Hirata K; Imai K; Shinomura Y
World J Gastroenterol; 2012 Dec; 18(45):6577-86. PubMed ID: 23236232
[TBL] [Abstract][Full Text] [Related]
19. Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer.
Chandarlapaty S; Sakr RA; Giri D; Patil S; Heguy A; Morrow M; Modi S; Norton L; Rosen N; Hudis C; King TA
Clin Cancer Res; 2012 Dec; 18(24):6784-91. PubMed ID: 23092874
[TBL] [Abstract][Full Text] [Related]
20. Alpelisib to treat breast cancer.
Copur MS
Drugs Today (Barc); 2020 Jun; 56(6):357-363. PubMed ID: 32525134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]